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Aulakh: Nonalcoholic Fatty Liver Disease

NONALCOHOLIC
FATTY LIVER DISEASE:
CAUSE TO TREATMENT
BY TAVLEEN AULAKH

INTRODUCTION
Imagine two individuals, both suffering from

source of energy and fat. The liver metabolizes,

concentrated in the hepatic cells, their livers are

depending on the body’s needs, and stores the

severe liver damage. With excess fat molecules
inflamed and scarred. These deteriorating livers are

also supplementing the development of chronic
obesity, diabetes, cardiovascular

diseases, and

hyperlipidemia. While one of these individuals is
a middle-aged male with a long history of alcohol

addiction and abuse, the other is only thirteen

years old and has never consumed alcohol. This

adolescent is suffering from nonalcoholic fatty liver

i.e. synthesizes and breaks down glucose and fat,
excess energy temporarily in the form of glycogen
and triglycerides (Manco, 2011). In the case of

alcohol-induced fatty liver, alcohol disrupts the fat

metabolism, causing an influx and accumulation of

free fatty acids in the liver (Orman et al., 2013).
NAFLD causes the same effect, driven primarily by
obesity (Nobili et al., 2009).

In fact, NAFLD prevalence rates parallel

disease (NAFLD).

the so-called “globesity” (global obesity) rates

in conjunction with almost every other system of

17% of children are considered overweight and

The liver is not an isolated organ; it works

the body, including the digestive, endocrine, and
circulatory system. For instance, the liver regulates

blood glucose levels, which is the body’s primary
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(Corte et al., 2012). In the United States alone,
obese by the Centers for Disease Control and

Prevention (CDC); of these, 52% have NAFLD
(Oddy et al., 2013). The proportion of children
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suffering from this disease represents 3%–13% of the

total US adolescent population. NAFLD is defined by
Anderson et al. (2015) as “the accumulation of fat in liver in the

absence of excessive alcohol consumption or other known liver

pathologies” (p. 2). The first adult case was reported in 1980 by

Ludwig, and in children by Moran in 1983 (Bozic et al., 2013).
From 1994 to 2004, its prevalence rate increased to 62.84%, and

within four years, it rose to 75.1% (Younossi et al., 2011). In
2015, it is currently the leading cause of liver disease in children

CHILDREN WITH NAFLD
ALSO HAVE A THIRTEENFOLD INCREASED RISK OF
DEATH OR OF REQUIRING A
LIVER TRANSPLANT

(Koot et al., 2015), with patients as young as three years of age
(Manco et al., 2008).

Since NAFLD is more common amongst Hispanic

American than African American populations, 45% versus
24% respectively, there may be a strong genetic predisposition

toward developing the disease (Marzuillo et al., 2014). However,
besides genetics, other factors can also significantly contribute

CONTEXTUAL FACTORS
THAT FAVOR NAFLD AND
THE TWO-HIT HYPOTHESIS

to the progression of the disease. These are explained in terms

of a double hit hypothesis, as shown in Figure 1. The first hit

Given that children have been exposed

refers to the accumulation of fat in liver cells. This sensitizes the

to an unhealthy lifestyle for a much

shorter period than adults, genetics may

liver to other factors, known collectively as the second hit, which

aggravate the liver further, leading to inflammation, scarring,
and if left untreated, even cancer (Veena et al., 2014). The

majority of pediatric NAFLD patients also show psychological
symptoms (St-Jules et al., 2013), reporting a significantly
lower quality of life compared to healthy children, 72% versus

83% respectively. Their symptoms include fatigue, depression,
insomnia, and poor school performance (Kistler et al., 2010).
Children with NAFLD also have a thirteen-fold increased risk
of death or of requiring a liver transplant as compared to their

healthy counterparts (Feldstein et al., 2009). Undoubtedly,

we are letting one preventable and reversible global epidemic,
obesity, exacerbate the spread of another preventable disease,
advancing both to chronic and fatal conditions. This article
examines how NAFLD develops in children and explores
preventative measures and treatment options, including lifestyle

modifications, in order to present the best interventions for

combatting the rapidly increasing rate of pediatric NAFLD.

https://cedar.wwu.edu/orwwu/vol6/iss1/6

play more of a dominant role in pediatric

NAFLD prevalence than adult NAFLD;

especially considering that in some cases,
children have the disease despite optimal

dietary and lifestyle habits (Nobili et al.,
2014). In fact, one study found that the

immediate family members of children
with NAFLD had a much higher
percentage of liver fat content, with

siblings at 9.3% and parents at 14% fat,
than the family members of the children
without the disease, whose siblings were

at 2.7% and parents at 7% (Schwimmer

et al., 2009). It is evident that NAFLD

is impacted by an individual’s genetics;
current research has identified multiple
genes that play a role in its development
(Dongiovanni et al., 2013).
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FIGURE 1. The Progression of NAFLD
NAFLD does not refer to one particular disease with a set of symptoms. Rather, it is a spectrum
of diseases, with three key stages. The earliest and most prevalent stage of NAFLD is called
simple steatosis (Ozgur et al., 2013). This stage involves the accumulation of triglycerides in the
liver cells due to an imbalance between the import and export of fatty acids (Nobili et al., 2009),
without significant liver inflammation (Roberts, 2007). While simple steatosis is asymptomatic and
reversible (Rafeey et al., 2009), if no action is taken to revert the liver’s condition, simple steatosis
progresses to nonalcoholic steatohepatitis (NASH). At this stage, liver cells contain harmful amount
of fat molecules, and there is significant inflammation with damaged and dead liver cells, which
causes scarring (Aqel & Dibaise, 2015). If the liver cells do not regenerate at the same rate as they
die, further scarring occurs, leading to cirrhosis (Ozgur et al., 2013), and in some cases, cancer
(Boursier & Diehl, 2015). Unlike simple steatosis, NASH is not asymptomatic, although it may be
reversible in some cases. However, once the disease has progressed to cirrhosis, the damage is
irreversible and fatal (Rafeey et al., 2009).
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The most apparent and globally conspicuous genetic

relationship of NAFLD is with the gene called PNPLA3,
patatin-like phospholipase domain-containing protein 3

(Lim et al., 2010), which is used to make an enzyme called
adiponutrin (Park et al., 2015). Adiponutrin is primarily
synthesized in liver and adipose (fat) tissue. In a healthy
individual, it acts as a triglyceride synthase in adipose cells, and

as a triglyceride hydrolase in liver cells. This means it can both
synthesize and break down triglycerides, depending on the cell

and the environmental factors that it is exposed to (Park et al.,
2015). In a NAFLD patient, a single nucleotide mutation, in

which cytosine is substituted with guanosine, creates a different
version of PNPLA3, a variant called rs738409-G allele, which

codes for a modified adiponutrin protein that lacks its hydrolytic
function (Marzuillo et al., 2014). This variant is correlated with
a diet consisting of highly sweetened beverages and excess

carbohydrates (Nobili et al., 2014). This adiponutrin variant

continues to synthesize triglycerides in fat tissue, as it would
in any healthy individual; however, it does not effectively break

down proliferating triglycerides in the liver (Park et al., 2015).
The accumulation of these fat particles causes severe steatosis,

inflammation, and fibrosis of the liver (Valenti et al., 2010).
The PNPLA3-G variant and modified adiponutrin are most
commonly found among the Hispanic population, which is also
the population with the highest NAFLD prevalence (Marzuillo

et al., 2014). Conversely, the population with the lowest rate
of NAFLD (African Americans) have been found to carry a
different variant of PNPLA3, called rs6006460-T-allele, which
is associated with low hepatic fat (Pan & Fallon, 2014).

Marzuillo has hypothesized that there are also relationships

Free Fatty Acids
Long chains of carbon atoms that are derived
from larger fat molecules
Gene
A piece of information on DNA that results in
a specific trait
Hyperlipidemia
A condition in which there are high levels of
fat molecules (lipids) in the blood
Lipid Peroxidation
A process in which molecules with oxygen
(known as free oxygen radicals) “steal”
electrons from lipids, preventing their proper
functioning
Mutation
A permanent change in a part of the DNA
Nucleotides
Organic molecules that make up the DNA

between NAFLD and other genes, such as the glucokinase

Oxidation
Loss of electrons from a molecule or atom

called glucokinase regulatory protein. This protein is responsible

Trait
A physiological characteristic of an organism
that may be inherited

regulatory (GCKR) gene. The GCKR gene codes for a protein
for mediating a liver enzyme called glucokinase (GCK), which
carries out glucose and fat metabolism (Tan et al., 2013). In

order to prevent synthesis of excess fatty acids, glucokinase

regulatory protein binds to GCK and inhibits its activity. An

https://cedar.wwu.edu/orwwu/vol6/iss1/6

Triglycerides
Specific type of fat molecule, derived from
glycerol, and three fatty acids
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of a two-hit hypothesis. The first hit refers to the factors that lead
to the accumulation of fat molecules in the liver, resulting in

NAFLD (Nanda, 2004); specifically, obesity, insulin resistance,
and hyperinsulinemia (Marzuillo et al., 2015). These factors,
along with others like hypertension and glucose regulation, are

categorized under metabolic syndrome (Alkhater, 2015). MtS,
or metabolic syndrome, is an umbrella term used for a group
of risk factors that lead to the development of cardiovascular
Fibrosis
Formation of excess fibrous connective
tissue in an organ; scarring
Glucose
A six carbon sugar that acts as a primary
source of energy for the body
Glycogen
A large sugar made up of multiple
glucose molecules; this acts as the
storage form of glucose/energy
Hyperinsulinemia
A condition in which the levels of insulin in the
blood are relatively higher than glucose levels

NAFLD patient, however, has a different

version of the GCKR gene, called

rs780094 allele. This variant produces a
dysfunctional GCKR, which is unable
to inhibit GCK. Consequently, GCK

continues to synthesize triglycerides,
which accumulate in the liver cells (Petta

et al., 2014). The prevalence of both the
PNPLA3 and GCKR variants are lowest

in the African American population.
By contrast, GCKR variant is more
prevalent in Han Chinese as compared

to high PNPLA3 in Hispanic Americans
(Lin et al., 2014).

While such genes predispose an

individual to NAFLD, the development

of the disease can be described in terms
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diseases and type 2 diabetes mellitus (Schwimmer et al.,
2008). Considering NAFLD exacerbates the progression
of cardiovascular diseases, it is believed to be the hepatic

manifestation of metabolic syndrome (Alkhater, 2015). While
all children with NAFLD have at least one other disease that is

categorized under MtS, obese adolescents are at five times the

risk of the syndrome. This link between NAFLD and metabolic

syndrome develops in early adolescence due to obesity-driven
insulin resistance (Manco, 2011).

Insulin resistance is defined as the body’s inability to

lower blood glucose levels in the fasting state, despite the rise
in insulin concentration in the blood (Mann et al., 2015). In a

healthy body, insulin triggers the muscle, fat, and liver cells to

uptake glucose from the bloodstream and either metabolize it

for energy or store it as glycogen. Simultaneously, it suppresses

the production of free fatty acids in both adipose and liver
tissue (Utzschneider & Kahn, 2006). The switch between

metabolizing fat or glucose depends on the availability and

demand of each macronutrient. In insulin-resistant patients,
however, the body loses its ability to make that shift. Neither

the adipose tissue nor the liver respond to insulin, glucose does
not get absorbed by the cells (Lee et al., 2015), and free fatty

acid synthesis continues in adipose and liver cells. Moreover,
the adipose cells fail to expand in order to store the excess fat,

which consequently gets delivered to the liver (Manco, 2011).
Much like NAFLD and metabolic syndrome, fat accumulation

and insulin resistance are a cyclical process. That is, the hepatic
fat (Marzuillo et al., 2015), as well as the increased rate of

triglyceride synthesis (Giorgio et al., 2013), exacerbates insulin

5
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resistance by preventing the activation of insulin receptors

cell signaling and storage). When lipid

Insulin sensitivity is 55% lower among obese adolescents

oxidized fatty acids are synthesized at

(Berardis & Sokal, 2014), worsening hepatic steatosis.

with NAFLD as compared to healthy children (Lee et al.,
2015). Indeed, obesity is a major risk factor for NAFLD
(Alkhater, 2015). Studies have shown that while 2–6% of the
pediatric population has been diagnosed with the disease, this

value significantly increases to 20–50% for obese children. It

is especially prevalent in pubertal children and adolescents

than in pre-pubertal children (Ackam et al., 2013). At the
onset of puberty, children go through hormonal imbalances, fat

redistribution throughout the body, and a decrease in insulin

peroxidation occurs at a high rate,
a toxic level. The damage from these

molecules overwhelms the repair capacity

of the cell, contributing to the fat stored
in the liver cells. Moreover, in another
cyclic process, lipid peroxidation causes
further

mitochondrial

dysfunction,

resulting in overproduction of oxygen
species (Takahashi et al., 2010).

ROS also cause an imbalance

sensitivity. Although most of these changes subside as a part

in cytokine production (Marzuillo et

in blood insulin levels is sustained throughout adolescence

inflammatory molecules from ectopic

of the maturation process (Cruz et al., 2005), the increase
(Loomba et al, 2009). Obesity, insulin levels, and triglyceride
synthesis are connected in a cyclical process; an increase in one
aggravates another.

These first hit factors then branch into different

pathologies, affecting the body as a whole. With proper
treatment, the condition is reversible (Lim et al., 2010). The

second hit, however, can perpetuate NAFLD and cause further

liver damage. This can lead to nonalcoholic steatohepatitis
(NASH), which makes reversal of the condition more

difficult (Marzuillo et al., 2015). The second hit involves lipid
peroxidation and inflammatory cytokine activation, both of

which are related to mitochondrial dysfunction (Giorgio et al.,
2013). Liver cells are rich in mitochondria, which are cellular
organelles that use free fatty acids and oxygen to synthesize

energy, carbon dioxide, and water (Basaranoglu et al., 2013). A
dysfunctional mitochondrion, however, is unable to efficiently
convert most of the oxygen into the required products, instead

al., 2015) by triggering the release of

fatty tissue (Fitzpatrick et al, 2012), while
simultaneously inhibiting the release of

anti-inflammatory molecules (Berardis
& Sokal, 2014). These inflammatory

cytokines include tumor necrosis factoralpha (TNF-α) and leptin. TNF-α not

only enhances insulin resistance (Roberts,
2007), but also activates a protein

which binds to the DNA to induce the

production of more ROS (Veena et al.,
Adipose Tissue
Body fat, found under the skin
Cytokine
Proteins responsible for cellular signaling.
They are an active part of the immune system
and regulate the maturation, growth, and
responsiveness of certain cells

creating molecules known as reactive oxygen species, or ROS

Hepatic Fat
Liver fat

processes. They carry out lipid peroxidation (Mylonas &

Insulin
A hormone produced and secreted by
pancreas to regulate the synthesis and
breakdown of carbohydrates and fats

(Nanda, 2004). These ROS negatively affect many cellular
Kouretas, 1999), oxidizing—and thus damaging—fatty acids

(necessary for important cellular processes such as intracellular

https://cedar.wwu.edu/orwwu/vol6/iss1/6
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2014). Given a high concentration of

(Giorgio et al., 2013). Therefore, it is important to recognize

liver cell death, and fibrosis (Manco et

with NAFLD tend to eat a diet higher in total saturated fat and

ROS, TNF-α induces liver inflammation,
al., 2007). Along with TNF-α, leptin

synthesis is also high in obese patients

with NAFLD. Leptin is a satiety
cytokine, which the brain fails to respond

to in cases of chronic obesity (Giorgio et
al., 2013). Insensitivity to leptin prevents

an individual from recognizing when

they are full, and so they continue to eat
and gain weight. Note that the damages

caused by ROS—the oxidation of lipids,
decrease in ATP production, and increase

the type of diet that promotes NAFLD progression. Children

refined sugars as compared to both obese and lean children who
do not have NAFLD (Mitchel & Lavine, 2014). Fructose, in

particular, is associated with NAFLD, as patients with a higher
intake of sugar-sweetened beverages are at an increased risk of

developing the condition regardless of their age, sex, and BMI

(Veena et al., 2014). Fructose is primarily metabolized in the
liver, through a mechanism very similar to that of ethanol (Lim

et al., 2010), which increases lipid synthesis. It also acts as a

pro-inflammatory mediator of NAFLD, contributing to liver
inflammation (Alkhater, 2015).

Fructose can also induce bacterial overgrowth and

in inflammatory cytokine release—are

increased bacterial permeability in the small intestine,

oxidative stress. It is due to the collective

circulation (Michail et al., 2015). This increase in permeability

together categorized under the term

effects of these events that the liver cells
die

(Ayala,

2014),

thus

causing

inflammation and scarring of the organ
(Basaranoglu et al., 2013).

Along with the aforementioned

physiological changes, adolescents also

gain increasing freedom to make their
own decisions, including those about

diet and physical activity. For many, these
decisions result in switching to a diet of
high calorie foods and a sedentary lifestyle

causing the movement of bacteria from the gut into the blood

leads to bacterial toxicity and the conversion of liver cells to
myofibroblasts, which release pro-inflammatory molecules such

as TNF-α (Alkhater, 2015). The toxins from the gut bacteria

also activate the complement system (Zhan et al., 2010),
further exposing liver to inflammation (Lim et al., 2010). One
of the main bacterial products involved in NAFLD is called
lipopolysaccharide (LPS). As an active component of an
endotoxin, LPS triggers a cascade of several enzymes involved
in the inflammatory pathway (Aqel & DiBaise, 2015).

PREVENTATIVE ACTIONS AND TREATMENT
FOR IMPROVING CHILD HEALTH

Ectopic Fat
The fat that accumulates in organs other
than adipose tissue, e.g. in the liver,
muscle tissues, pancreas and arteries

Before treatment can begin, a diagnosis must be made. According

Fructose
Fruit sugar made up of molecules
of glucose and sucrose

the symptoms are unrelated to the liver (Nanda, 2004). There is

Intracellular Cell Signaling
Part of a communication system in the body
that activates and coordinates cell actions

a diagnosis of obesity (Roberts, 2007). Consequently, NAFLD
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to many studies, this is a fairly difficult process primarily
because the early stages of NAFLD are either asymptomatic or

also a general lack of non-invasive diagnostic tests (Anderson et

al., 2015). A physical examination is of no help as it results in
diagnosis is based on either elevated levels of aminotransferase

7
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(ALT), an enzyme that is secreted by damaged liver cells, or

by decreased levels of adiponectin. However, even these results

are not definitive diagnostic criteria. In fact, there is no proper
threshold of ALT with respect to age and sex to indicate
NAFLD (Anderson et al., 2015). The only sure way to diagnose

Complement System
Consists of small proteins that are synthesized
in the liver, which complement antibodies and
phagocytes in the immune system

NAFLD is to first disprove all other possibilities (Hourigan et

improves compliance, which may be a

between simple steatosis and NASH (Roberts, 2007).

and adolescent patients. Second, dietary

al., 2015), then carry out a liver biopsy, especially to distinguish

Once diagnosed, treatment for pediatric NAFLD must

occur as soon as possible, with a focus on reversing steatosis and

promoting healthy growth and development (Roberts, 2007).
The best way known is through weight loss, which decreases
the concentration of free fatty acids in liver, increases insulin
sensitivity by metabolizing glucose rather than fat, and reduces

the synthesis of ROS (Mitchel & Lavine, 2014). Thus, dietary

changes and adequate exercise are considered the first line of
defense against progression of NAFLD to NASH (Nobili

et al., 2009). A low glycemic index (GI) diet is appropriate
for weight loss (Loomba et al., 2009), consisting of 50–60%
carbohydrates, 23–30% fats, and 15–20% proteins. The intake of
high fructose beverages must be reduced as greater amounts of

sugar stimulate synthesis of fatty acids in the body, proliferating
the fat in the liver (Manco et al., 2008). Since excess fructose is

also associated with insulin resistance, steatosis, and oxidative

stress, decreasing its consumption will significantly improve
liver health (Manco, 2011). Changing to a healthier diet can

also significantly decrease the blood levels of ALT (Nobili et al.,
2009). Some studies have recorded lower ALT and triglyceride

levels after a twelve-month treatment with an omega-3 fatty
acid DHA (Berardis & Sokal, 2014). Omega fatty acids, such

zchallenge when working with children

and physical requirements must be

continuously reevaluated to account for
the child’s developmental rate, changes in

body weight, height, etc. (St. Jules et al.,
2013). It is extremely important that the

child’s needs for growth are met (Berardis

& Sokal, 2014), especially during puberty.
Physical changes should not be the only

aspect accorded importance. During this
period, most children and adolescents are

already sensitive about their body image

and may have low self-esteem. Therefore,
overemphasizing the need for weight
reduction should be avoided to prevent
negative psychological effects (St. Jules et

al., 2013). It is in fact harmful to lose a
great amount of weight in a short period
of time, as this may increase liver injury
(Nobili et al., 2009). In order to ensure

gradual weight loss, children should

begin with moderate exercise like brisk

as DHA and EPA, have been shown to reduce fat deposits by
activating certain cellular pathways that induce breakdown of
fatty acids and inhibit their synthesis (Manco et al., 2008).

Physicians and researchers agree that proper diet

is significant in reversing NAFLD in pediatric patients.
However, it is important to cater the lifestyle modifications
to each individual; this serves several purposes. First, it

https://cedar.wwu.edu/orwwu/vol6/iss1/6
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walking or swimming (Veena et al.,

The only weight loss medication approved by the FDA

2014). Although forty-five minutes of

for pediatric use is Orlistat. Although this drug inhibits excess

(Nobili et al., 2009) for treatment and as

vitamins. Nonetheless, it may reverse steatosis and insulin

aerobic exercise per day is recommended
positive reinforcement (Roberts, 2007),
more studies are required to determine

the benefits of exercise on its own,
as well as with dietary changes (Deldin
& Lee, 2013).

Further research is also required

in the pharmacological field, since
there is no drug treatment approved

specifically for NAFLD (Veena et al.,
2014). Pediatric NAFLD treatments
are especially difficult because they

must account for several factors, such
as growth and development, hormonal

changes, and rapid lifestyle modifications.

fat absorption, it also interferes with absorption of fat-soluble

resistance (Mitchel & Lavine, 2014). Another medication,
metformin, is well documented as a safe and effective treatment

for diabetes (Loomba et al, 2009) and insulin resistance (Nanda,

2004), and so is often prescribed to target that aspect of NAFLD.
However, many studies have shown that although metformin
helps to decrease insulin resistance, it does not improve liver

condition any more than lifestyle changes (Manco, 2011).
Another class of insulin sensitizers called thiazolidinediones

have been shown to improve insulin sensitivity and reverse
steatosis in adults (Nanda, 2004), but are not yet prescribed

to children due to the lack of scientific support as well as the
known side effects, which include weight gain, cardiovascular
disease, and heart failure (Alkhater, 2015).

Antioxidants such as vitamin E supplements are also

Any medication prescribed must be

considered to be a possible treatment option. In some cases,

an adolescent body (Berardis & Sokal,

the liver cells in NASH (Berardis & Sokal, 2014). However,

unresponsive towards the changes in
2014). For now, given that NAFLD

progresses due to the cyclical process
involving

obesity,

diabetes,

insulin

resistance, and oxidative stress, those
are the pathologies targeted by most
medicines (Nanda, 2004).

Bile
A fluid produced by the liver that is
discharged into the small intestine to assist
in the digestion of ingested fats
Noninvasive
Refers to treatment methods that do not
require incisions, and lessen pain, healing
time, and risk of infection
Steatosis
Refers to accumulation of
lipids inside a cell
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supplements have been shown to decrease the ballooning of
much like insulin sensitizers, there are either not enough

cohort studies on their long term effects (Veena et al., 2014),
or the few studies that have been done show no sign that
vitamin E is more effective than lifestyle changes (Sarkhy et
al., 2014). On the other hand, if vitamin E is administered with

UDCA, an acid that deactivates bile to prevent the killing of
liver cells, in conjunction with proper diet and exercise, ALT

levels show improvement (Cho et al., 2012). In comparison,
DHA, an omega-3-fatty acid, results in decreases in both the

ALT and triglyceride levels (Alkhater, 2015). Probiotics have

been found to have a similar effect (Berardis & Sokal, 2014);
in fact, probiotics are being considered as highly valuable
anti-inflammatory agents that work by decreasing bacterial
translocation (Mitchel & Lavine, 2014).

In extreme chronic cases, and as a last resort, surgery

may be considered. Bariatric surgery and transplant is seen as

9
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a treatment option for children whose lifestyle changes were

further research to develop new diagnostic

stage. There are not enough studies on the long term safety of

less expensive.

unsuccessful or for those who were diagnosed in the chronic
pediatric bariatric surgery and its effects on hepatic steatosis

testing that is noninvasive, accurate, and

More long-term research is also

and inflammation. However, it has been shown to improve ALT

needed to determine the efficacy of specific

banding and Roux-en-Y gastric bypass. Despite variable long-

that are seen as options for NAFLD

levels (Alkhater, 2015). There are two types of surgeries, gastric
term results, banding is believed to have the least amount of risk

and is reversible. The gastric bypass procedure is believed to be

more efficient, though it may lead to nutrient deficiencies and
protein malnutrition (Mitchel & Lavine, 2014).

Transplantation in NAFLD patients is often complicated

by the conditions that come with the disease such as obesity,
diabetes, and hyperlipidemia (Nanda, 2004). A condition
called post-transplant metabolic syndrome is seen in some

children who undergo liver transplants. Moreover, the
immunosuppressive therapy that follows a transplant can lead
to diabetes, hypertensions, cardiovascular diseases, and steatosis

(Nobili & de Ville de Goyet, 2013). Prospective donors,

diets, supplements, and medications

treatment. Currently, it is extremely
important for NAFLD patients to be

served by a multidisciplinary healthcare
team.

Dieticians,

hepatologists,

psychologists, and cardiologists need to
evaluate the cases and be involved with

the patient (Nobili et al., 2009). For

pediatric patients, family involvement
is also necessary to maintain nutritional
knowledge

and

implement

physical

activity—along with clinical treatment.

especially those at risk for developing NAFLD themselves,
must first undergo liver biopsies (Mathur et al., 2007).

CONCLUSION
Nonalcoholic fatty liver disease (NAFLD) is an increasingly

prevalent condition that interferes with the proper growth
and development of children. It has a wide array of causative

factors, and its effects extend beyond the liver to the whole body.
There is a need for discussions about NAFLD at the public

level, as fatty liver is mistakenly only associated with alcohol
consumption. Obesity, heart disease, and hypertension are rarely
associated with the liver, despite being strong contributors to

the progression of NAFLD. Since it is imperative that children
with NAFLD be diagnosed as soon as possible, increasing

knowledge on the disease will allow more cases to be caught in
time. In fact, all children—especially those at risk of obesity, and

those with a family history of fatty liver—should be screened
for NAFLD on a regular basis. This highlights the dire need for

https://cedar.wwu.edu/orwwu/vol6/iss1/6

Hepatologists
Individuals who study the liver and
its pathologies
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